McLean Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
McLean Asset Management's BMY Position: Q1 2026 in Review
McLean Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.2% in Q1 2026, buying an estimated $4.37K and bringing the position to 6,540 shares worth $397K. The position accounts for 0.07% of the portfolio, ranked #111.
McLean Asset Management first reported a position in BMY in Q4 2020 and has held it in 22 quarters since. The position peaked at $590K in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- McLean Asset Management held 6,540 shares of Bristol-Myers Squibb worth $397K as of Q1 2026.
- McLean Asset Management bought 75 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.37K.
- Bristol-Myers Squibb made up 0.07% of McLean Asset Management's portfolio in Q1 2026, its #111 holding.
- McLean Asset Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 22 quarters since.
- McLean Asset Management's Bristol-Myers Squibb position peaked at $590K in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on McLean Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.